BioTuesdays

Tag - Kaveri Pohlman

Cullinan Logo
Markets

BTIG starts Cullinan Oncology at buy; PT $20

BTIG initiated coverage of Cullinan Oncology (NASDAQ:CGEM) with a “buy” rating and price target of $20, citing a burgeoning pipeline and unique biology that could open avenues for a broad range of opportunities. The...

November 21, 2022
NexImmune-Logo
Markets

BTIG starts NexImmune at buy; PT $5

BTIG initiated coverage of NexImmune (NASDAQ:NEXI) with a “buy” rating and price target of $5. The stock closed at $2.28 on May 31. NexImmune exploits signals naturally provided by dendritic cells (DCs) to activate...

May 31, 2022
Markets

BTIG starts Oncternal at buy; PT $5

BTIG launched coverage of Oncternal Therapeutics (NASDAQ:ONCT) with a “buy” rating and $5 price target. The stock closed at $1.73 on Feb. 23. Oncternal is a clinical-stage biotechnology company focused on a diverse...

February 24, 2022
CytomX
Markets

BTIG starts CytomX Therapeutics at buy; PT $16

BTIG initiated coverage of CytomX Therapeutics (NASDAQ:CTMX) with a “buy” rating and price target of $16. The stock closed at $7.02 on Nov. 12. CytomX is a clinical-stage biotechnology company focused on developing...

November 15, 2021
Sonnet-BioTherapeutics
Markets

BTIG starts Sonnet BioTherapeutics at buy; PT $5

BTIG launched coverage of Sonnet BioTherapeutics (NASDAQ:SONN) with a “buy” rating and price target of $5. The stock closed at 56 cents on Sept. 14. Sonnet is an early-stage biotechnology company working to develop...

September 15, 2021